Coherus BioSciences, Inc.
CHRS · Nasdaq · United States
Share price · CHRS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CHRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-14.3%
Nothing announced by CHRS that day or the session before.
- 10 Nov 2026-21.6%
- 29 Oct 2026-22.6%
- 18 Sep 2026+9.8%
Nothing announced by CHRS that day or the session before.
- 18 Aug 2026+16.5%
- 6 Aug 2026-12.8%
- 12 May 2026-12.3%
- 11 May 2026+11.4%
- 13 Feb 2026-19.9%
Nothing announced by CHRS that day or the session before.
- 23 Jan 2026+29.6%
Share of unusual movement by asset
For each asset, the share of CHRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerBiliary Tract CancerNasopharyngeal Carcinoma Cholangiocarcinoma |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (8)
March 2027 (1)
What to watch
May 2027 (2)
June 2027 (1)
What to watch
July 2027 (1)
What to watch
November 2027 (2)
December 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $14M | $23M | $54M+ $30M short-term inv. | $39M-$34M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $14M | $21M | $83M+ $22M short-term inv. | $21M-$62M operating cash flow | report ↗ |
| 2026-Q1 | $12M | $22M | $115M+ $52M short-term inv. | $38M-$58M operating cash flow | report ↗ |
| 2025-Q3 | $12M | $27M | $104M+ $88M short-term inv. | $36M-$46M operating cash flow | report ↗ |
| 2025-Q2 | $10M | $26M | $217M+ $21M short-term inv. | —-$47M operating cash flow | report ↗ |
| 2025-Q1 | $7.6M | $24M | $83M | $57M-$26M operating cash flow | report ↗ |
| 2024-Q3 | $71M | $22M | $98M | $11M-$62M operating cash flow | report ↗ |
| 2024-Q2 | $65M | $22M | $160M | $13M$60M operating cash flow | report ↗ |
| 2024-Q1 | $77M | $28M | $260M | —-$47M operating cash flow | report ↗ |
| 2023-Q3 | $75M | $26M | $81M+ $51M short-term inv. | $40M-$54M operating cash flow | report ↗ |
| 2023-Q2 | $59M | $23M | $73M+ $72M short-term inv. | $43M-$39M operating cash flow | report ↗ |
| 2023-Q1 | $32M | $34M | $17M+ $112M short-term inv. | $76M-$69M operating cash flow | report ↗ |
| 2022-Q3 | $45M | $46M | $287M | $87M-$37M operating cash flow | report ↗ |
| 2022-Q2 | $60M | $42M | $276M | $50M-$50M operating cash flow | report ↗ |
| 2022-Q1 | $60M | $83M | $326M | $96M-$54M operating cash flow | report ↗ |
| 2021-Q3 | $83M | $54M | $361M+ $108M short-term inv. | $39M$14M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $42M | $109M | $89M+ $83M short-term inv. | —-$139M operating cash flow | report ↗ |
In fiscal year 2025, Coherus reported revenue of $42.17M, down 84.2% YoY, and R&D expense of $108.89M, up 16.7% YoY. Cash and cash equivalents were $89.12M at year-end, with total cash, cash equivalents and marketable securities of $172.1M. The company reported net income of $168.02M for 2025, including a $351.1M contribution from discontinued operations; net loss from continuing operations was $183.1M, or $(1.56) per diluted share, versus $215.4M, or $(1.88) per diluted share, in 2024.
LOQTORZI net revenue more than doubled to $40.8M in 2025 from $19.1M in 2024. The company reduced secured and convertible debt by 90% from $480M to $38.8M over 2024-2025, and raised approximately $7.9M in net proceeds from an October 2025 equity sale and approximately $47.0M from a February 2026 public offering. Clinical updates included six-year overall survival data from the Phase 3 JUPITER-02 trial presented at ESMO Asia, ongoing tagmokitug combination studies with initial data readouts expected in mid-2026 and 2H 2026, an ongoing randomized Phase 2 casdozokitug/toripalimab/bevacizumab trial in 1L uHCC with a first readout expected in mid-2026, and a planned Phase 1b study of tagmokitug with J&J’s pasritamig in mCRPC expected to start in 2H 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $267M | $93M | $126M | —-$20M operating cash flow | report ↗ |
| 2023-FY | $257M | $109M | $103M+ $15M short-term inv. | $59M-$175M operating cash flow | report ↗ |
| 2022-FY | $211M | $199M | $64M+ $128M short-term inv. | $73M-$241M operating cash flow | report ↗ |
| 2021-FY | $327M | $363M | $418M | $72M-$37M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-05 | Newton Charles W. · director | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-05 | Wahlstrom Mats · director | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-05 | O'Donnell-Tormey Jill · director | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-05 | Ryan Michael Lee · director | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-05 | Newcomer Lee Nisley · director | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-05 | Karachun Rita A · director | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-05 | Satvat Ali J. · director | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-05 | Newton Charles W. · director | Award / grant (derivative) | 60,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 156 reporting institutions held 59.1M shares ($95.5M, 38.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 10,365,074 | $17.5M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 5,452,762 | $9.2M |
| 3 | SAMSARA BIOCAPITAL, LLC | 3,428,571 | $5.8M |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 3,121,578 | $5.3M |
| 5 | Kohlberg Kravis Roberts & Co. L.P. | 3,036,076 | $5.1M |
| 6 | STATE STREET CORP | 2,325,859 | $3.9M |
| 7 | TWO SIGMA INVESTMENTS, LP | 2,302,001 | $3.9M |
| 8 | Alyeska Investment Group, L.P. | 2,250,000 | $3.8M |
| 9 | CM Management, LLC | 2,100,000 | $3.5M |
| 10 | TANG CAPITAL MANAGEMENT LLC | 1,886,748 | $3.2M |
| 11 | Hudson Bay Capital Management LP | 1,704,980 | $2.9M |
| 12 | PANAGORA ASSET MANAGEMENT INC | 1,459,310 | $2.5M |
| 13 | Propel Bio Management, LLC | 1,420,550 | $2.4M |
| 14 | AQR CAPITAL MANAGEMENT LLC | 1,206,046 | $2.0M |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,155,901 | $2.0M |